Bellicum Pharma (BLCM) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Bellicum Pharmaceuticals Provides Operational Update and Reports Financial Results for the Second Quarter Ended June 30, 2015
August 13, 2015 4:05 PM EDTConference call and webcast to be held Thursday, August 13, 2015 at 5 p.m. Eastern
HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today reported financial results for the second quarter of 2015, and provided an update on the Company's recent developments.
Over the last six months, we made substantial progress across all of our controlled immunotherapy programs, said Tom Farrell, President and CEO of Bellicum Pharmaceuticals. In our lead BPX-501 clinical program, we have been pleased with... More
